Company: BNBX
Filing Date: 2025-01-10
Form Type: S-1/A
Source: 0001104659-25-002521
Chunk: 32

Company: BNB PLUS CORP.
Filing Date: 2025-01-10
Form: S-1/A
Chunk 32
---
 forecasts and market research, which we believe to be reliable
based on our management’s knowledge of the industry. Forecasts are particularly likely to be inaccurate, especially over long periods
of time. In addition, we do not necessarily know what assumptions regarding general economic growth were used in preparing the third-party
forecasts we cite. Statements as to our market position are based on the most currently available data. While we are not aware of any
misstatements regarding the industry data presented in this prospectus and the documents incorporated by reference into this prospectus,
our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the
heading “Risk Factors” in this prospectus and the documents incorporated by reference into this prospectus.

<div align='center'>USE OF PROCEEDS</div>

We will not receive any proceeds from the sale
of the shares of Common Stock by the Selling Stockholders. However, we will receive proceeds from the exercise of the Private Placement
Warrants by the Selling Stockholders to the extent they are exercised for cash. We estimate that the maximum proceeds that we may receive
from the exercise of the Private Placement Warrants, assuming all the Private Placement Warrants are exercised at their exercise price
of $0.32, will be $13,325,000. We do not know, however, whether any of the Private Placement Warrants will be exercised for cash or,
if any of the Private Placement Warrants are exercised for cash, when they will be exercised. It is possible that the Private Placement
Warrants will expire and never be exercised.

There are circumstances under which the Private
Placement Warrants may be exercised on a cashless basis, including pursuant to the alternative cashless exercise mechanism of the Series D
Warrants. In these circumstances, even if the Private Placement Warrants are exercised, we may not receive any proceeds, or the proceeds
that we do receive may be significantly less than what we might expect. We intend to use the aggregate net proceeds from the exercise
of the Private Placement Warrants for the further development of our Therapeutic DNA Production Services, as well as for general corporate
purposes, including working capital. The actual allocation of proceeds realized from the exercise of these Private Placement Warrants
will depend upon the amount and timing of such exercises, our operating revenues and cash position at such time and our working capital
requirements. The Selling Stockholders will pay any expenses incurred by the Selling Stockholders for brokerage, accounting, tax or legal